Induction Chemotherapy,Radiochemotherapy, Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer

Inclusion Criteria: * Male or female patients with histologically proven adenocarcinoma of the rectum (tumour located below the peritoneum), * T3/4 or any node positive disease (clinical stage according the TNM classification system) * No evidence of metastatic disease. * The disease must be considered either resectable at the time of entry or thought to become resectable after preoperative chemoradiation. * Age 18 years and more * WHO Performance Status 0-2 * No prior radiotherapy, chemotherapy or any targeting therapy for rectal cancer * Adequate hematological, hepatic and renal function Ability to swallow tablets * Signed informed consent * Patients must be willing and able to comply with the protocol for duration of the study Exclusion Criteria: * Malignancy of the rectum other than adenocarcinoma * Any unrested synchronous colon cancer * Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin * Significant heart disease (uncontrolled hypertension despite of medication (\> 150/100 mmHg), NYHA class III or IV heart disease,unstable angina or myocardial infarction within the past 1 year prior the study entry, history of significant ventricular arrhythmia requiring treatment) * Pregnant or lactating patient * Females with a positive or no pregnancy test unless childbearing potential can be otherwise excluded (amenorrheic for at least 2 years,hysterectomy or oophorectomy)